← Back to Search

Procedure

Field Expansion for Blindness in Right Eye

N/A

Recruiting

Led By Jaehyun Jung, Ph.D.

Research Sponsored by Massachusetts Eye and Ear Infirmary

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

No medical health issues such as seizures, motor movements problem

Loss of vision in one eye (no light perception/enucleation/evisceration) for >1 year

Timeline

Screening 3 weeks

Treatment Varies

Follow Up approximately 2 sessions, up to 3 hours for each session, any time within 2 month period

Awards & highlights

Study Summary

This trial is developing a device called a multiplexing prism that helps people who have lost one eye to see a wider field of view. They are testing a simpler design and way of fitting the device

Who is the study for?

This trial is for people who have lost vision in one eye for more than a year, but still have good vision (better than 20/32) in their other eye without any field defects. They should not have health issues like seizures or motor movement problems.Check my eligibility

What is being tested?

The study is testing a device called a multiplexing prism designed to widen the visual field for those with sight in only one eye. The focus is on evaluating a new simplified design and how easy it is to fit this device to help with vision.See study design

What are the potential side effects?

Since this trial involves an assistive device rather than medication, traditional side effects are not applicable. However, there may be discomfort or adjustment challenges when using the multiplexing prism.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I do not have seizures or problems with motor movements.

Select...

I have been blind in one eye for more than a year.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ approximately 2 sessions, up to 3 hours for each session, any time within 2 month period

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~approximately 2 sessions, up to 3 hours for each session, any time within 2 month period

This trial's timeline: 3 weeks for screening, Varies for treatment, and approximately 2 sessions, up to 3 hours for each session, any time within 2 month period for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Field expansion from multiplexing prism

Secondary outcome measures

Maximum extent of nasal visual field with multiplexing prism

Trial Design

1Treatment groups

Experimental Treatment

Group I: Field ExpansionExperimental Treatment1 Intervention

Field of view on the nasal side (same side as the blind eye) with and without multiplexing prism

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

National Eye Institute (NEI)NIH

547 Previous Clinical Trials

1,402,147 Total Patients Enrolled

Massachusetts Eye and Ear InfirmaryLead Sponsor

106 Previous Clinical Trials

12,939 Total Patients Enrolled

Jaehyun Jung, Ph.D.Principal InvestigatorSchepens Eye Research Institute

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the uppermost limit for participant enrollment in this research endeavor?

"Indeed, the data available on clinicaltrials.gov confirms that this trial is presently seeking individuals to participate. The study was initially posted on December 27th, 2023 and most recently updated on December 28th, 2023. Recruitment aims to enroll a total of 10 participants from a single site."

Answered by AI

Are individuals currently able to participate in this research study?

"Indeed, the information available on clinicaltrials.gov confirms that this study is presently in the recruitment phase. The trial was initially posted on December 27th, 2023 and last updated on December 28th, 2023. At a single site, there are spots for ten participants to enroll in the trial."

Answered by AI